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A Research article on Formulation and Characterisation of Topical Nanoemulgel of 
Terbinafine 
ABSTRACT: The aim is to develop nanoemulgel as a novel drug delivery system using 
carbopol 934 as a gelling agent. The objective behind the formulation is to avoid dosing 
frequency and to increase the stability and bioavailability and avoiding the first pass metabolism. 
The formulation was prepared by using oleic acid, carbopol 934, span 20, propylene glycol in 
different ratios and analyzed by pseudo tertiary phase diagram. All the prepared nanoemulgel 
shows satisfactory physiochemical properties. The stability and particle size is been determined 
by zeta potential. The highest drug release was found in F4 formulation was 82% follows non-
fickian mechanism. 
KEY WORDS: Topical drug delivery, Nano emulsion, Nano emulgel, Antifungal drug, tertiary 
phase. 
 
INTRODUCTION 
Nanoemulgel has emerged as one of the most interesting topical delivery system as it has dual 
release control system i.e. Hydrogeland nanoemulsion. Nanoemulgel having nanosize (10 to 
100μm) rapidly penetrates and deliver active substance deeper and quicker. Gelling agent 
promotes better stability of nanoemulsion by reducing the surface and interfacial tension and also 
enhancing viscosity of the aqueous phase for drug administration topically
1,2
. Drug delivered 
through nanoemulgel has better adhesion on the surface on the surface of the skin and high 
solubilizing capacity which leads to larger concentration gradient towards the skin, hence 
influences better skin penetration. Nanoemulsions are thermodynamically stable, transparent, or 
translucent dispersion of two immiscible liquids, such as oil and water stabilized by an interfacial 
film of surfactant and cosurfactant molecules having the droplet size of less than 100 nm. It also 
retard dosing frequency of drug.
3,4
 
Terbinafine [(2E)-6,6-dimethylhept-2-en-4-yn-1yl](methyl)(naphthalene-1-ylmethyl)amine is a 
broad spectrum antifungal drug active against ermatophytes. Dermatophytes cause infections of 
the skin, hair and nails, obtaining nutrients from keratinized material. Some of these skin 
infections are known as ringworm or tinea. Terbinafine has first pass effect due to this shows 
poor oral bioavailability. It inhibits ergoterol synthesis by inhibiting squalene epoxidase, an 
enzyme that is a part of fungal cell membrane synthesis pathway. Because terbinafine prevent 
conversion of squalene to lanosterol, ergosterol cannot be synthesized, and caused fungal cell 
lysis.
5
 
 The objective is to develop a most effectivetopical preparation to avoid first pass metabolism of 
drug, with enhanced pharmacological action on local area, enhanced penetration of drug with the 
help of penetration enhancer, improved and better drug release profile of the drug by preparing a 
suitable nanoemulgel for the treatment of fungal infection.
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MATERIALS AND METHOD 
Terbinafine was obtained from Yarrow chem. product uttarakhand India , Oleic acid, Span 20, 
propylene glycol, Carbopol 934were obtained from Molychem. pvt. Ltd. All other ingredients, 
chemicals and solvents used were of analytical grade. 
 
PREFORMULATION STUDIES  
Fourier Transform Infrared (FTIR) spectral analysis 
 IR analysis was done on IR spectrometer with KBr disc. In IR thespectrum was recorded in the 
wavelength region of 4000 to 400cm
-1
. 10mg of drug was mixed with KBr and triturated then it 
was placed in holder and pressed to form a pellet. It was placed under IR beam and a spectrum 
was obtained on computer. The IR spectrum of drug exhibit maxima only at the same 
wavelength as that of similar preparation of the corresponding reference standard, thus IR 
spectrum of substance being examined should be concordant with the reference spectrum of the 
drug. 
 Solubility Study
7 
Solubility of Terbinafine was determined in various oils suchas oleic acid, isopropyl myristate, 
clove oil, castor oil and olive oil by shake flask method. An excess amount of drug was taken in 
10 ml of the oil in vials, and mixed using vortex mixer. The vials were then kept at 25 ± 1
0
C in 
an isothermal shaker. The samples were then centrifuged at 3,500rpm for 15min. The supernatant 
was filtered through whatman (no. 41) filter paper.  Thefiltrate was suitably diluted. The amount 
of drug dissolved in the oil was determined using UV spectrophotometer at their respective 
wavelength. 
 Partition coefficient 
It is a ratio of unionized drug distribution between organic and aqueous phase at equilibrium. It 
was determined in n- octanol: water system, by taking 25ml of both n-octanol and water in 
separating funnel. Shake this mixture for 30 minutes and keep it for 24 hour. Then 10 mg drug 
mixed with saturated solution of n-octanol:water in separating funnel. The separating funnel was 
shaken for 24 hours. The two phases was separated and the amount of the drug in aqueous phase 
was analyzed by UV at 282.7 nm after appropriate dilution.  
partition coeffiecient=(conc.in oil phsae)/(conc.in aq.phase) 
SPECTROSCOPIC STUDIES 
Preparation of standard stock solution -100mg of drug dissolve in 10ml of methanol in 100ml 
volumetric flask and volume was adjusted with methanol upto the mark to obtained 1000µg/ml 
(solution A). The solution was filtered through whatman filter paper No. 41 
Determination of λmax 
A10ml solution was pipette out from solution A in 100ml volumetricflask and diluted with 
methanol up to the mark to obtained 100µg/ml. The solution was filtered through whattman filter 
paper No. 41(solution B). From these aliquots of 0.2ml, 0.4ml, 0.6ml, 0.8ml and 1ml were 
pipette out in to a 10ml volumetric flask and diluted to methanol up to the mark and get the 
concentration 2 µg/ml, 4 µg/ml, 6 µg/ml, 8 µg/ml, 10 µg/ml respectively. Absorbance of this 
solution was measured at 282.7nm using UV spectroscopy against blank (methanol). 
 
Preparation of Phosphate buffer pH 7.4 (PBS) 
Dissolve 2.3gm of disodium hydrogen phosphate, 0.19gm of potassium dihydrogen phosphate 
and 8gm of sodium chloride in sufficientwater to produce 1000ml. adjust the pH if necessary. 
 
Calibration curve of terbinafine in Phosphate buffer pH 7.4 solution 
A10mg of drug dissolve in 20ml of methanol and 8ml of phosphate buffer in a 100ml volumetric 
flask and volume was adjusted up to the mark to obtained 1000µg/ml. The solution was filtered 
through whatman filter paper No. 41(solution A). From this solution an aliquot of 1ml was 
withdrawn and diluted to 10ml with PBS pH7.4 to get concentration of 100 µg/ml (solution B), 
filtered out all solution by whatman filter no. 41. Fromthese aliquots of 0.2ml, 0.4ml, 0.6ml, 
0.8ml and 1ml were pipette out in to a 10ml volumetric flask and diluted to PBS pH 7.4 upto the 
 mark and get the concentration 2 µg/ml, 4 µg/ml, 6 µg/ml, 8 µg/ml, 10 µg/ml respectively. 
Absorbance of this solution was measured at 282.7nm using UV spectroscopy against blank 2:8. 
(Methanol: PBS pH7.4) 
Preparation of nanoemulgel 
Table 1. Screening and selection of oil, surfactant and co-surfactant 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Construction of pseudo ternary phase diagram
8 
The phase diagram was developed using water titration method to determine the appropriate 
components and their concentration ranges. Oleic acid was used as the oil phase, span 20 and 
propylene glycol was selected as surfactant and cosurfactant, respectively. Distilled water was 
used as an aqueous phase. Surfactants and cosurfactant [Smix] were mixed in different weight 
ratios (1:1, 1:2 and 2:1) to determine the optimum ratio which can result in maximum 
nanoemulsion area. For each phase diagram, oil and specific Smix were mixed well in different 
ratios from 1:9 to 9:1 in different vials. The ratio of oil to surfactant varied as 1:9, 2:8, 3:7, 4:6, 
5:5, 6:4, 7:3, 8:2, and 9:1. The mixtures weretitrated with the aqueous phase, and visual 
observations were made for transparent and easily flow able oil-in-water (o/w) nanoemulsion. 
The physical state of the true nanoemulsion was marked on a pseudoternary phase diagrams with 
one axis representing the aqueous phase, and the other representing a mixture of surfactant and 
cosurfactant at fixed weight ratios (Smix ratios). 
 
Oils 
Name of Excipient Solubility(mg/ml) 
Olive oil 32.92 
Castor oil 19.12 
Oleic acid 49.22 
isopropyl myristate 43.16 
Clove oil 39.36 
Surfactants 
Tween 80 98.42 
Span 20 106.31 
polyethylene gycol 4000 72.18 
Co- Surfactants 
propylene glycol 86.04 
Glycerine 63.82 
 Figure 1 Pseudo-ternary phase diagram at 1:1 weight ratio of surf:cosurf 
 
 
Figure 2 Pseudo-ternary phase diagram at 2:1 weight ratio of surf:cosurf 
 
 
Figure 3 Pseudo-ternary phase diagram at 1:2 weight ratio of surf:cosurf 
Formulation of Terbinafine loaded nanoemulsion 
The experimental design based on a three component system: Oil phase (oleic acid), Smix 
(span20: propylene glycol) and aqueous phase (water). Thetotal conc. of the three phases 
summed is 100%. Based on the results of pseudo ternary diagram appropriate range of the 
component was selected. The o/w NE was prepared by water titration method. The formulations 
were further sonicated (Sonica ultrasonic, 2000 MH,) for 5 minutes and stored at room 
temperature until their use in subsequent studies. 
  
Figure 4 Different Nanoemulsion formulation 
CHARACTERIZATION OF NANOEMULSION
9 
 Physical Characterization
 
The prepared nanoemulsion formulations wereinspected visually for their color, appearance, 
consistency, phase separation and homogeneity. 
 Droplet Size and Size Distribution 
The globules size distribution, polydispersity index and droplet size of the resultant 
nanoemulsion was determined by dynamic light scatteringwith zetasizer, 1ml of the optimized 
nanoemulsion formulation was diluted with water to 10mL in a test tube, and gently mixed by 
glass rod and then analyzes the fluctuations in light scattering due to Brownian motion of the 
particles. Light scattering was monitored at 25°C at a 90° angle. Globule diameter and 
distribution was obtained. 
 Zeta-Potential Analysis
10  
Zeta potential is a technique which is used to measure the surface charge properties and further 
the long term physical stability of nanoemulsion. The potential is measure of the electric 
potential at the slip plane between the bound layer of diluents molecules surrounding the particle 
and the bulk solution. A higher level of zeta potential results in greater electro-static repulsion 
between the particles, minimizing aggregation/ flocculation. 
 
Measurement of pH 
1ml of nanoemulsion was dissolved in 10 mL of distilled water. At first pH meter reading was 
calibrated using known pH solution (pH4 and pH7) and the electrode was then dipped in to NE 
formulation and constant reading was noted.  
Measurement of Viscosity 
The viscosity of true nanoemulsion was determined without any dilution using Brookfield 
viscometer. The sample (30mL) was taken in a beakerand allowed to equilibrate for 5min before 
measuring the reading using a spindle at 2, 2.5, and 5, 6, 10, 12, 20, 30rpm. At each speed, the 
corresponding reading on the viscometer was noted. 
Centrifugation 
This technique of centrifugation helps to determine the phase separation of nanoemulsion. 10ml 
NE was placed in centrifugation tube and put in apparatus at 3000rpm for 30mint and examined 
for any phase separation. 
Dye Test
11 
 It is used to check the nature of the nanoemulsion (o/w or w/o). Watersoluble dye is added in o/w 
NE. The NE takes up the color uniformity. Conversely, if the emulsion is w/o type and the dye 
being soluble in water, the emulsion takes up the colour only in dispersed phase and emulsion is 
not uniformly colored. 
FORMULATION OF NANOEMULSION GEL
12 
1% carbopol 934 was selected as a gelling agent. Carbopol 934 solution (1% carbopol 934 added 
in warm water with continuous stirring) added drop wise into the nanoemulsion with continuous 
stirring until the nanoemulsion convert into nanoemulgel. 
 
Figure 5 Preparation of Nanoemulgel 
CHARACTERIZATION OF NANOEMULGEL 
 pH determination 
One gram of nanoemulgel was dissolved in 10 ml of distilled water and the pH meter was prior 
standardized with standard buffers of pH 4 and pH 7. 
Viscosity 
The viscosity of formulations is determined using Brookfield DV-III at temperature 25°C. 
50grams of the sample is tested using a 50 ml capacity vessel using spindle 5 at different speed. 
Spreadability
13 
An excess of emulgel (about 1 g) under study was placed onthis ground slide. The emulgel 
preparation was then sandwiched between this slide and second glass slide having same 
dimension as that of the fixed ground slide. The second glass slide is provided with the hook. 
Weight of 100 g was placed on the top of the two slides for 5 min to expel air and to provide a 
uniform film of the emulgel between the two slides. Measured quantity of weight (35g) was 
placed in the pan attached to the pulley with the help of hook. Time in seconds taken by two 
slides to slip off from emulgel and placed in between the slides under the direction of certain 
load. Lesser the time taken for separation of two slides, better the spreadability. It is calculated 
by using the formula. 
S=m×l/t 
Where   is spreadability,  is weight placed on upper slide,   is length of upper slide, and   is the 
time taken 
Drug Content Determination
14 
Quantity of Terbinafine in nanoemulsion gel was determined by UV-Spectrophotometer. 1.0 g of 
formulation was accurately weighed, dissolved in 100 ml of methanol: phosphate buffer (2:8). It 
was filtered and diluted if required. Absorbance was determined using UV spectrophotometer at 
282.7nm.
 
  
In-Vitro Release Study of Terbinafine Containing Formulation
 15,16 
The In-vitro drug release studies were carried out using a modified Franz diffusion cell (With 
effective diffusion area 2.54 cm2 and 20 ml cell volume). The formulation was applied on 
dialysis membrane (which was previously soaked in Phosphate buffer pH 7.4 for 24 hours) 
which was sandwiched between donor and receptor compartment of the Franz diffusion cell. 
Phosphate buffer pH 7.4 was used as dissolution media.  Thetemperature of the cell was 
maintained at 37±0.2ᵒC by kept it in water bath. This whole assembly was kept on a magnetic 
stirrer and the solution was stirred continuously using a magnetic bead at 50rpm. The samples 
(1ml aliquots) were withdrawn at suitable time interval and analyzed for drug content by UV 
visible spectrophotometer at 282.7 nm after appropriate dilutions.  
 
 
Figure 6 Franz Diffusion cell 
In-Vitro Drug Release Kinetics 
17, 18
 
To study the release kinetics of in-vitro drug release, data was applied to kinetic models such as 
zero order, first order, Higuchi and Korsmeyer-Pappas.,  
In short, the result obtained from in-vitro release studies were plotted in four kinetic models of 
data treatment as follows:  
 Cumulative % drug release Vs. Time (zere order rate kinetics) 
 Log cumulative % drug release Vs. Time (First order rate kinetics) 
 Cumulative % drug release Vs. Time √T (Higuchi’s classical diffusion equation) 
 Log cumulative % drug release Vs.  log Time (Korsmeyer Peppas equation) 
 RESULTS 
The pre-formulation studies were performed as per given procedures. The results given below: 
Physical examination 
Color: White to off white  
Appearance: Crystalline powder 
Taste: Tasteless 
Partition Coefficient 
The partition coefficient (log P) was determined byshake flask method. The logP value of drug 
sample was obtained 5.51.  
Spectroscopy studies 
Determination of λ max (absorption maxima) 
10mg Terbinafine was dissolve in 10ml of ethanol than 1ml of this solution was taken and 
diluted upto 10ml with ethanol. This dilution were scanned for determined absorption maxima in 
range 200-300nm. The observed absorbance maxima were found to be 282.7 nm. UV spectrum 
of Terbinafine was interpreted absorption maxima (λ max) shown in table: 
Table 2 Determination of λ max (absorption maxima) of Terbinafine 
 Wavelength Interpretation Inference 
200-300 nm Scanning range Drug absorption maxima 
(λ max) 282.7 nm. 282.7nm Highest peak 
 
Standard Calibration curve of Terbinafine in Ethanol 
The calibration curve of terbinafine was determined in the conc. range of 0.5-3.0µg/ml. 
Preparation of Calibration curve of Terbinafine in Ethanol 
S.No Concentration(µg/ml) Absorbance (nm) 
1 0 0 
2 0.5 0.0086 
3 1.0 0.0165 
4 1.5 0.0274 
5 2.0 0.0368 
6 2.5 0.0485 
7 3.0 0.0573 
 
 Preparation of Calibration curve of terbinafine in 7.4 pH Phosphate buffer 
The calibration curve of Terbinafine in 7.4 pH PBS was determined in conc. range of 2-10µg/ml. 
 
Figure 7 Calibration curve of terbinafine in 7.4 pH Phosphate buffer 
IR Spectra of Nanoemulsion (Compatibility studies) 
The compatibility of nanoemulsion containing all excipients oleic acid as oily phase, span20 as a 
surfactant and propylene glycol as a co-surfactants and drug (Terbinafine), by FTIR. It was 
found that there was no chemical reaction between drug and excipients because in the 
characteristics peaks of terbinafine, there no any changes wasobserved when compared to the IR 
spectra of pure drug. 
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Figure 8 IR spectra of nanoemulsion (Terbinafine+ Oleic acid+ Span20+ Propylene glycol) 
CHARACTERIZATION OF NANOEMULSION 
 Particle Size Analysis 
In the all formulation the particle size range were observed from 95.96 to 536 (nm) and the 
polydispersity index was found to be 0.400 to 0.709. The particle size study explain that the 
effect of different ratio of surfactant, cosurfactant, oil and water. F4 has 144 nm zeta average due 
to 1:2 proportion of surfactant and cosurfactant and less amountof oil phase. Higher size average 
was found to be 536 nm for formulation F1. 
Table 3 Particle Size Analysis of Drug Loaded Nanoemulsion Formulation 
S. No Formulation code Polydispersity Index Particles size 
(nm) 
1 F1 0.728 521 
2 F2 0.709 95.96 
3 F3 0.652 536 
4 F4 0.400 144 
5 F5 0.462 215.8 
 
 
 
 
Figure 9 Graphical representation of Polydispersity Index 
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Figure 10 Graphical representation of Zeta Average 
From the all 4 formulations, best formulations graphs and figure are given below. First graph is 
F2, its size was found to be 95.96 nm and polydispersity index was found to be 0.709. Second 
graph is F4, its size was found to be 144 nm and polydispersity index was found to be 0.400. 
Third graph is F5, its size was found to be 2.15.8 nm and polydispersityindex was found to be 
0.462. 
 
 
Figure 11 Particle size Analysis of drug loaded Nanoemulsion (Formulation2) 
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Figure 12 Particle size Analysis of drug loaded Nanoemulsion (Formulation4) 
 
Figure 13 Particle size Analysis of drug loaded Nanoemulsion (Formulation5) 
 Zeta Potential of Nanoemulsion 
Zeta Potential of all formulation was found to be -4.32 to -32.6. The higher zeta potential of any 
formulation shows more stability because due to the high zeta potential of particles are not allow 
getting aggregate because of electrical repulsive force between particles. 
Table 4 Zeta Potential of Nanoemulsion 
S.No Formulation code Zeta potential 
1 F1 -10.7 
2 F2 -24.8 
3 F3 -4.32 
4 F4 -32.6 
5 F5 -19.7 
  
 
Figure 14 Graphical representation of Zeta Potential 
 
 Figure 15 Zeta potential of drug loaded nanoemulsion F2 
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Figure 16 Zeta potential of drug loaded nanoemulsion 
 
Figure 17 Zeta potential of drug loaded nanoemulsion 
pH determination 
19 
The pH value for NE formulation was recorded 5.73 to 6.82. The pH of the NE was found to be 
within the range of pH of skin and would not cause any irritation tothe skin 
 Viscosity Measurement
20 
A Brookfield Viscometer was used to measure the viscosityof nanoemulsion and nanoemulgel by 
different spindle speeds. Viscosity reveals the rheological properties of all formulation. 
Table 5 Viscosity of Nanoemulsion Formulation 
VISCOSITY OF NANOEMULSION (centipoises) 
 Formulation code F1 F2 F3 F4 F5 
Spindle speed 
(rpm) 
0.3 960 982 861 946 883 
0.6 829 830 720 871 739 
1.5 740 724 648 730 647 
3 629 604 525 627 521 
6 552 526 424 552 458 
12 385 437 335 382 317 
30 240 352 227 218 241 
 
 
Figure 18  Graphical Representation of viscosity Nanoemulsion formulation 
Table 6 Viscosity of Nanoemulsion Gel Formulation 
VISCOSITY OF NANOEMULSION Gel (centipoises) 
Formulation code F1* F2* F3* F4* F5* 
Spindle speed 
(rpm) 
0.3 9600 12000 6000 8400 6500 
0.6 4000 8000 4000 6200 2200 
1.5 2000 7600 2600 2300 1650 
3 1700 3700 1820 1200 940 
6 1400 2300 1300 730 820 
12 1158 1600 780 620 760 
30 720 900 480 320 550 
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Figure 19 Graphical Representation of viscosity Nanoemulsion Gel formulation 
Spreadability of Nanoemulsion Gel 
Spreadability of NEG was determined by spreadability apparatus. Spreadability is measured on 
the basis of ‘slip’ and ‘Drag’ characteristics of nanoemulsion gel. Spreadability is an important 
property of topical formulation from patient compliancepoint of view. 
Table 7 Spreadability of Nanoemulsion Gel 
Spreadability of Nanoemulsion Gel 
S.No Formulation code Spreadability 
1 F1* 5.14 
2 F2* 5.46 
3 F3* 6.15 
4 F4* 6.47 
5 F5* 6.31 
 
Drug Content of Nanoemulsion Gel 
Drug content is the drug concentration in gellified nanoemulsion, which was measured by UV 
spectrophotometer. The range of percentage drug content of nanoemulsion gel was 75.3% to 
92.7%. The range of percentage drug content of formulations was found to be satisfactory. 
Table 8 Percentage drug content of nanoemulsion gel 
% Drug Content Of NEG 
S.No Formulation Code Drug content 
1 F1* 88.9% 
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 2 F2* 90.3% 
3 F3* 81.9% 
4 F4* 92.7% 
5 F5* 86.3.7% 
 
 IN-VITRO PERCENT CUMULATIVE DRUG RELEASE OF NEG 
The in-vitro % cumulative drug release studies of NEG were found to be 66.90% to 82.69%. All 
the formulation shows different release rate because of differentratio of surfactant and co-
surfactant. F4* NE shows best drug release 82.69% in 6hrs and F2* shows lowest drug release 
66.90% in 6hrs. 
Table 9  In-vitro % cumulative drug release of NEG 
S.No Time 
(hr) 
Time 
(min) 
% cumulative drug release of NEG 
F1* F2* F3* F4* F5* 
1 0 0 0 0 0 0 0 
2 0.25 15 4.08 3.55 5.36 6.73 5.11 
3 0.5 30 11.44 8.74 12.22 13.57 9.24 
4 1 60 19.35 16.32 20.08 19.73 17.32 
5 1.5 90 28.90 26.13 28.80 28.61 22.19 
6 2 120 39.21 35.99 39.21 35.91 29.04 
7 2.5 150 47.65 43.66 48.01 44.23 36.92 
8 3 180 54.41 50.49 56.17 52.07 40.12 
9 4 240 60.73 56.54 63.47 61.92 48.28 
10 5 300 66.39 62.12 70.35 73.01 56.19 
11 6 360 71.58 66.90 76.96 82.69 68.19 
  
Figure 20 Graphical representation of % Cumulative Drug Release of NEG 
In-Vitro Drug Release Kinetics Modeling of NEG 
For the determination of drug release data of all NEG formulation were fitted into zero order 
kinetics, first order kinetics, koresymer papas release kinetics, higuchi release kinetics, Bakar 
losandale release kinetics to know the drug release pattern from theNEG formulation.  
 The results of model dependent methods for curve estimation were used to develop 
regression models that have the best R
2
 values. It is evident from the regression value of NEG 
followed the drug release of formulation F1* and F2* followed the Baker losandale release 
pattern because R
2
 was 0.985 and 0.983 and n value was found to be 0.000 and 0.000 this is may 
be due to their surf: cosurf ratio. F3* followed the 1
st
 order release pattern because R
2
 was 0.994 
and n value was found to be -0.001. F4* and F5* followed the Koresymer release pattern with 
non-Fickian anomalous diffusion (0.45<n<0.89) because R
2
 was 0.996 and 0.997 and n value 
was found to be 0.781 and 0.805.F4* and F5* shows best R
2
 value. 
 
 
 
 
 
Table No.10  Drug release kinetics eq. and R
2
 values of all formulation  
 
S.No Formulation 
code 
F1* F2* F3* F4* F5* 
Zero order R
2
 value 0.928 0.933 0.948 0.982 0.982 
n 0.002 0.002 0.002 0.002 0.001 
Ist order R
2
 value 0.982 0.978 0.994 0.983 0.986 
n -0.001 -0.00 -0.001 -0.001 -0.000 
Higuchi 
Model 
R
2
 value 0.970 0.965 0.972 0.969 0.966 
n 0.043 0.040 0.045 0.046 0.036 
Koresymer 
papas 
R
2
 value 0.969 0.975 0.985 0.996 0.997 
n 0.885 0.932 0.838 0.781 0.805 
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 Bakar 
losandale 
R
2
 value 0.985 0.983 0.977 0.931 0.923 
n 0.000 0.000 0.000 0.000 0.000 
 
Graphs of Release kinetics 
1. First order release kinetics 
First order kinetics graph was plotted between log cumulative% of drug remaining versus 
time. 
 
Figure 21 Graphical representation of 1
st
 order release kinetics (F4*) 
 
2. Koresymer papas release kinetics 
Koresymer papas release kinetics graph was plotted between log cumulative % drug 
releases versus log time. 
 
 Figure 22 Graphical representation of Koresymer papas release kinetics (F4*) 
 
3. Higuchi release kinetics 
Higuchi release kinetics graph was plotted between cumulative % drug release versus 
square root of time. 
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Figure 23 Graphical representation of Higuchi release kinetics (F4*) 
 
4. Zero order release kinetics 
In zero order kinetics graph was plotted between cumulative amount of drug release 
versus time. 
 
Figure 24 Graphical representation of Zero order release kinetics (F4*) 
 
5. Bakar losandale release kinetics 
In bakar losandale release kinetics graph was plotted between [d(mt/m∞)]/dt versus root 
of time inverse. 
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Figure 25 Graphical representation of Bakar losandale release kinetics (F4*) 
CONCLUSION 
The principle object of the present experimental work was to make a most effective topical 
preparation for avoid the first pass metabolism of terbinafine in the treatment of antifungal 
infections with maximum drug release and reduce g.i.t side effects. The studies showed that 
changing the concentration of oil, surfactant, cosurfactant and double distilled water as aqueous 
phase has an impact on the behavior and thermodynamic stability of the nanoemulsion. There 
was a spontaneous formation of clear nanoemulsion, presumably due to orientation of surfactant 
and cosurfactant at the interface, which is a direct consequence of high thermodynamic stability 
at the attained interface of the system. In this study, nanoemulsion and NEG were prepared and 
evaluated. The results showed that nanoemulsion components had significant effect on the 
response. The nanoemulsion formulation containing %surf: co surf 48.91, %oil 5.43 and %water 
45.65 was best for forming NEG. For all studies the nanoemulsion gel F4* has best release and 
most effective formulation.  
 Drug delivery through nanoemulsion gel is a promising area for continued research with 
the aim of achieving controlled release with enhanced bioavailability and for drug targeting to 
affected sites. 
FUTURE SCOPE: 
 To carry out in–vivo drug release studies and bioavailability studies for the formulated 
product. 
 To perform the clinical trials for making the exercise commercially available. 
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